Art. -Nr.: HY-111772

Elexacaftor

(Synonyms: VX-445)

51 Cited Publications

Kundenbewertung

Based on 51 publication(s) in Google Scholar

Elexacaftor (VX-445, Compound 1) is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR). Elexacaftor (VX-445, Compound 1) facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.26%
CAS. Nr.: 2216712-66-0
Formel: C₂₆H₃₄F₃N₇O₄S
Molecular Weight:597.65

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Elexacaftor Chemical Structure

CAS. Nr.: 2216712-66-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- Clinical Trial
Chemical Information
Publications (51)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

CFTR^[1].

In Vitro

Elexacaftor (VX-445) is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function. Elexacaftor (VX-445) has the potential to treat cystic fibrosis. VX-445-Tezacaftor-VX-770 significantly improves Phe508del CFTR protein processing, trafficking, and chloride transport to a greater extent than any two of these agents in dual combination^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 2216712-66-0
Appearance Solid
Molecular Weight 597.65
Formel C₂₆H₃₄F₃N₇O₄S
Color White to off-white
SMILES

CC1(C)C[C@H](C)CN1C2=C(C(NS(C3=CN(C)N=C3C)(=O)=O)=O)C=CC(N4C=CC(OCC(C)(C(F)(F)F)C)=N4)=N2
Synonyms

VX-445
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (51)

All WBBio/Physico-chemical AssayOthers

Sort by:

Journal Impact Factor

Am J Respir Crit Care Med

Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence. [Abstract]

2021 Nov 15;204(10):1231-1235. PMID: 34379998

Elexacaftor purchased from MedChemExpress. Usage Cited in: Am J Respir Crit Care Med. 2021 Nov 15;204(10):1231-1235. [Abstract]

Western blot of CFTR variances transiently expressed in HEK293 (left) or CFBE (right) cells. Cells were transfected with indicated CFTR variances overnight and then treated with VX445 (Elexacaftor: 2 μM) /VX661 or DMSO for 24 hours.
J Clin Invest

Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator (CFTR) correctors VX-445 and VX-121. [Abstract]

2024 Jul 2:e176328. PMID: 38954478

Elexacaftor purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Jul 2:e176328. [Abstract]

Subsequent to amiloride, short-circuit current (Isc) was increased by the C2 CFTR correctors VX-445 (10 μM).

Elexacaftor purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Jul 2:e176328. [Abstract]

Recording of force in millinewtons (mN) over time from a single mesenteric artery showing preconstriction with the prostaglandin mimetic U46619 (1 × 10−7 to 5 × 10−7 M), after which the ability of increasing concentrations of VX-445 (Elexacaftor) to induce vasorelaxation was assessed. We added 0 Ca2+ at the end to determine maximal vasorelaxation.
J Clin Invest

Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators. [Abstract]

2021 Aug 16;131(16):e150398. PMID: 34166230

Elexacaftor purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2021 Aug 16;131(16):e150398. [Abstract]

Human airway epithelia from CFTR-ΔF508 donors were treated for 48 hours with a combination of elexacaftor (3 μM), tezacaftor (18 μM), and ivacaftor (1 μM), either alone or in the presence of TNF-α+IL-17. pHASL was measured using SNARF-1-dextran.
Mol Ther

PKC activators improve the function of biogenesis-deficient CFTR channels. [Abstract]

2026 Jul 1;34(7):4212-4225. PMID: 41925277
Br J Pharmacol

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators. [Abstract]

2025 Aug 20. PMID: 40831301
J Med Chem

Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). [Abstract]

2024 Aug 22;67(16):13891-13908. PMID: 39137389
JCI Insight

Targeting PI3Kγ anchoring enhances CFTR membrane localization and modulator efficacy via PKD1. [Abstract]

2026 Mar 23;11(6):e198846. PMID: 41869727

Elexacaftor purchased from MedChemExpress. Usage Cited in: JCI Insight. 2026 Mar 23;11(6):e198846. [Abstract]

Representative immunogold electron microscopy images showing the distribution of overexpressed F508del-CFTR-GFP in HEK293T cells. Cells were treated for 24 hours with DMSO (Veh), ETI (3 μM VX-445, 10 μM VX-661, and 1 μM VX-770) plus control peptide (ETI + 25 μM CP), or ETI plus PI3Kγ MP (ETI + 25 μM PI3Kγ MP). HEK293T cells expressing WT CFTR-GFP served as positive controls.
JCI Insight

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. [Abstract]

2020 Sep 17;5(18):e139983. PMID: 32853178
Cells

Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes. [Abstract]

2022 Dec 16;11(24):4096. PMID: 36552859
Int J Mol Sci

Restoration of Defective CFTR in Human Nasal Respiratory Epithelial Cells by CFTR Modulators and mRNA Transfection. [Abstract]

2026 Feb 23;27(4):2063. PMID: 41752197
Int J Mol Sci

Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR. [Abstract]

2025 May 31;26(11):5306. PMID: 40508114
Int J Mol Sci

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes. [Abstract]

2023 Sep 26;24(19):14539. PMID: 37833986
Int J Mol Sci

Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination. [Abstract]

2023 Jun 19;24(12):10358. PMID: 37373505
Int J Mol Sci

Rare Trafficking CFTR Mutations Involve Distinct Cellular Retention Machineries and Require Different Rescuing Strategies. [Abstract]

2021 Dec 21;23(1):24. PMID: 35008443
Int J Mol Sci

IRE1α Is a Therapeutic Target for Cystic Fibrosis Airway Inflammation. [Abstract]

2021 Mar 17;22(6):3063. PMID: 33802742
J Cyst Fibros

Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment. [Abstract]

2026 Jun 4:S1569-1993(26)01638-3. PMID: 42243036
J Cyst Fibros

A functional comparison of vanzacaftor/tezacaftor/deutivacaftor and elexacaftor/tezacaftor/ivacaftor in patient-derived intestinal organoids with rare CFTR variants. [Abstract]

2026 Jun 16:S1569-1993(26)01643-7. PMID: 42303492
J Cyst Fibros

Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers. [Abstract]

2025 May;24(3):552-561. PMID: 39979195
J Cyst Fibros

A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function. [Abstract]

2025 Jan;24(1):164-174. PMID: 39532588
J Cyst Fibros

Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background. [Abstract]

2023 May;22(3):525-537. PMID: 36543707

Elexacaftor purchased from MedChemExpress. Usage Cited in: J Cyst Fibros. 2023 May;22(3):525-537. [Abstract]

Elexacaftor/Tezacaftor (elexa/teza; 3 μM/10 μM; 24 h) combination causes a significant increase in the expression of the mature protein, with no changes in the expression of the immature, core-glycosylated form (B band) in Epithelia.
J Cyst Fibros

CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation. [Abstract]

2021 May;20(3):452-459. PMID: 32674984
Am J Physiol Cell Physiol

(R)-vanzacaftor potentiates BKCa channels in the absence of CFTR correction or potentiation. [Abstract]

2025 Oct 1;329(4):C1130-C1138. PMID: 40920663
Am J Respir Cell Mol Biol

Distinct Responses of Cystic Fibrosis Epithelial Cells to SARS-CoV-2 and Influenza A Virus. [Abstract]

2025 Mar;72(3):308-319. PMID: 39311876
Am J Physiol Cell Physiol

KCa3.1 potentiation stimulates Cl- secretion in F508del and G551D CFTR-corrected primary human bronchial epithelial cells. [Abstract]

2022 Oct 1;323(4):C1215-C1230. PMID: 36062876
Am J Physiol Cell Physiol

TNFα and IL-17 alkalinize airway surface liquid through CFTR and pendrin. [Abstract]

2020 Aug 1;319(2):C331-C344. PMID: 32432926
PNAS Nexus

VX-445 (elexacaftor) inhibits chloride secretion across human bronchial epithelial cells by directly blocking KCa3.1 channels. [Abstract]

2025 Jul 4;4(7):pgaf211. PMID: 40688096
J Physiol

The apical mucus layer alters the pharmacological properties of the airway epitheliumy. [Abstract]

2025 May;603(9):2619-2632. PMID: 40047394
Hum Gene Ther

SP-101, A Novel Adeno-Associated Virus Gene Therapy for the Treatment of Cystic Fibrosis, Mediates Functional Correction of Primary Human Airway Epithelia From Donors with Cystic Fibrosis. [Abstract]

2024 Sep;35(17-18):695-709. PMID: 39155805
Structure

Triangulating variation in the population to define mechanisms for precision management of genetic disease. [Abstract]

2022 Aug 4;30(8):1190-1207.e5. PMID: 35714602
iScience

Defective CFTR modulates mechanosensitive channels TRPV4 and PIEZO1 and drives endothelial barrier failure. [Abstract]

2024 Aug 9;27(9):110703. PMID: 39252977
iScience

In silico analysis and theratyping of an ultra-rare CFTR genotype (W57G/A234D) in primary human rectal and nasal epithelial cells. [Abstract]

2023 Oct 12;26(11):108180. PMID: 38026150
Front Physiol

CFTR Correctors and Antioxidants Partially Normalize Lipid Imbalance but not Abnormal Basal Inflammatory Cytokine Profile in CF Bronchial Epithelial Cells. [Abstract]

2021 Feb 4;12:619442. PMID: 33613309
Microbiol Spectr

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth. [Abstract]

2025 Sep 2;13(9):e0227524. PMID: 40736245
J Biol Chem

A nonnatural peptide targeting the A-kinase anchoring function of PI3Kγ for therapeutic cAMP modulation in pulmonary cells. [Abstract]

2024 Nov;300(11):107873. PMID: 39393573
J Cell Sci

Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs. [Abstract]

2022 Mar 1;135(5):jcs259002. PMID: 35060604
Orphanet J Rare Dis

CFTR modulators response of S737F and T465N CFTR variants on patient-derived rectal organoids. [Abstract]

2024 Sep 13;19(1):343. PMID: 39272186
Respir Med

Theratyping as a tool to guide clinical decision-making in patients with suspected cystic fibrosis and variants currently ineligible for CFTR modulator therapy. [Abstract]

2025 Dec:250:108478. PMID: 41241150
Glycoconj J

Effect of CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor on lipid metabolism in human bronchial epithelial cells. [Abstract]

2025 Feb;42(1):1-14. PMID: 39797966
PLoS One

Alternative splicing and residual function potentially expand the therapeutic landscape of the CFTRdele2ins182 variant. [Abstract]

2025 Sep 16;20(9):e0330974. PMID: 40956828
Respir Investig

Functional rescue of CFTR in rectal organoids from patients carrying R334W variant by CFTR modulators and PDE4 inhibitor Roflumilast. [Abstract]

2024 Mar 27;62(3):455-461. PMID: 38547757
STAR Protoc

Protocol for generating airway organoids from 2D air liquid interface-differentiated nasal epithelia for use in a functional CFTR assay. [Abstract]

2023 Jun 12;4(3):102337. PMID: 37314920
University of Lisbon

2026.
J Pers Med

Functional, Cohort-Level Assessment of CFTR Modulator Responses Using Biobanked Nasal Epithelial Cells from Individuals with Cystic Fibrosis. [Abstract]

2026 Jan 15;16(1):51. PMID: 41590543
bioRxiv

2025 April 11.
bioRxiv

2025 February 27.
bioRxiv

Chronic pancreatitis patient-derived organoids reveal new paths to precision therapeutics. [Abstract]

2025 Nov 14:2024.10.30.620903. PMID: 41279927
bioRxiv

2024 October 17.
bioRxiv

2024 August 16.
University of Kentucky

2022 Aug.
J Pers Med

Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers. [Abstract]

2022 Apr 14;12(4):632. PMID: 35455747
J Pers Med

Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators. [Abstract]

2020 Nov 5;10(4):209. PMID: 33167369

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 125 mg/mL (209.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6732 mL

8.3661 mL

16.7322 mL

5 mM

0.3346 mL

1.6732 mL

3.3464 mL

10 mM

0.1673 mL

0.8366 mL

1.6732 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Alexander Russell Abela, et al. MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR , PHARMACEUTICAL COMPOSITIONS , METHODS OF TREATMENT , AND PROCESS FOR MAKING THE MODULATOR. US 20180162839 A1.

[2]. Keating D, et al. VX-445-Tezacaftor-VX-770 in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 Oct 25;379(17):1612-1620. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6732 mL	8.3661 mL	16.7322 mL	41.8305 mL
	5 mM	0.3346 mL	1.6732 mL	3.3464 mL	8.3661 mL
	10 mM	0.1673 mL	0.8366 mL	1.6732 mL	4.1831 mL
	15 mM	0.1115 mL	0.5577 mL	1.1155 mL	2.7887 mL
	20 mM	0.0837 mL	0.4183 mL	0.8366 mL	2.0915 mL
	25 mM	0.0669 mL	0.3346 mL	0.6693 mL	1.6732 mL
	30 mM	0.0558 mL	0.2789 mL	0.5577 mL	1.3944 mL
	40 mM	0.0418 mL	0.2092 mL	0.4183 mL	1.0458 mL
	50 mM	0.0335 mL	0.1673 mL	0.3346 mL	0.8366 mL
	60 mM	0.0279 mL	0.1394 mL	0.2789 mL	0.6972 mL
	80 mM	0.0209 mL	0.1046 mL	0.2092 mL	0.5229 mL
	100 mM	0.0167 mL	0.0837 mL	0.1673 mL	0.4183 mL

Keywords

Elexacaftor

51 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Elexacaftor

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

FDA-Approved Drug Library

Autophagy Compound Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Pediatric Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Classic FDA-Approved Drug Library

Publications Citing Use of MedChemExpress (MCE) Elexacaftor

Biologische Aktivität

Chemical Information

Publications (51)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Elexacaftor

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

FDA-Approved Drug Library

Autophagy Compound Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Pediatric Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Classic FDA-Approved Drug Library

Publications Citing Use of MedChemExpress (MCE) Elexacaftor

Biologische Aktivität

Chemical Information

Publications (51)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Elexacaftor Related Classifications

HY-111772 Related Classifications